In this webinar, Robert Lowrey and David Siderovski will discuss novel AI-driven drug discovery approaches targeting ...

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...

These assays continue to infill the shallow, northern portion of the S1 ‘Starter Pit' with shallow, higher-grade intersections, and indicate potential refinement to modelling where vertical zones of ...

Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how a robust anti-drug antibody assay ...

Copyright: © 2024 The Author(s). Published by Elsevier Ltd. We developed and assessed the analytical performance of a sample-sparing, multiplexed, microsphere-based ...

Advances in precision oncology have transformed cancer treatment, offering life-saving therapies to patients with limited options. However, the development of personalized medicine introduces ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Caitlin Mills (left) is a lecturer in systems biology at Harvard Medical School (HMS; MA, USA) and Director of Preclinical Pharmacology in the Laboratory of Systems Pharmacology (LSP) at HMS. Caitlin ...

Hello and welcome to this edition of the Biotech bi-weekly, a fortnightly listicle bringing you a rapid review of the latest happenings and developments in the biotech industry! As ever with a new ...